An investigation for investors in Onconova Therapeutics Inc (NASDAQ:ONTX) shares over potential securities laws violations by Onconova Therapeutics was announced.

San Diego, CA -- (SBWire) -- 01/20/2016 --An investigation for shareholders in Onconova Therapeutics Inc (NASDAQ:ONTX) shares over potential securities laws violations by Onconova Therapeutics was announced.

Investors who purchased shares of Onconova Therapeutics Inc (NASDAQ:ONTX), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm focuses on whether a series of statements by Onconova Therapeutics regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On December 4, 2015, post-market, Onconova Therapeutics Inc announced that the FDA had placed a full clinical hold on the investigational new drug application for briciclib, one of Onconova Therapeutics' secondary clinical-stage product candidates, following a drug product lot testing failure due to visible particulates. Onconova will be required to undertake appropriate remedial actions prior to re-initiating the clinical trial. Onconova Therapeutics Inc said that it previously reported that enrollment in the next cohort of a Phase 1 clinical trial of briciclib was expected to resume upon completion of quality control testing of the drug. Shares of Onconova Therapeutics Inc (NASDAQ:ONTX) declined to as low as $1.19 per share on December 7, 2015.

On January 15, 2016, NASDAQ:ONTX shares closed at $0.60 per share.

Those who purchased shares of Onconova Therapeutics Inc (NASDAQ:ONTX) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com